Synthesis and evaluation of FAK inhibitors with a 5-fluoro-7H-pyrrolo[2,3-d]pyrimidine scaffold as anti-hepatocellular carcinoma agents

Hanyi Tan,Yue Liu,Chaochao Gong,Jiawei Zhang,Jian Huang,Qian Zhang
DOI: https://doi.org/10.1016/j.ejmech.2021.113670
IF: 7.088
2021-11-01
European Journal of Medicinal Chemistry
Abstract:<p>Focal adhesion kinase (FAK) is a ubiquitous intracellular non-receptor tyrosine kinase, which is involved in multiple cellular functions, including cell adhesion, migration, invasion, survival, and angiogenesis. In this study, a series of 7<em>H</em>-pyrrolo[2,3-<em>d</em>]pyrimidines were designed and synthesized according to the E-pharmacophores generated by docking a library of 667 fragments into the ATP pocket of the co-crystal complex of FAK and PF-562271 (PDB ID: <a href="http://www.rcsb.org/pdb/explore.do?structureId=3BZ3">3BZ3</a>). The 5-fluoro-7<em>H</em>-pyrrolo[2,3-<em>d</em>]pyrimidine derivatives demonstrated excellent activity against FAK and the cell lines SMMC7721 and YY8103. 2-((2-((3-(Acetamidomethyl)phenyl)amino)-5-fluoro-7<em>H</em>-pyrrolo[2,3-<em>d</em>]pyrimidin-4-yl)amino)-<em>N</em>-methylbenzamide (<strong>16c</strong>) was selected for further bioactivity evaluations <em>in vivo</em>, including preliminary pharmacokinetic profiling in rats and toxicity assays in mice, and tumor growth inhibition studies in a xenograft tumor model. The results showed that <strong>16c</strong> did not affect the body weight gain of the animals up to a dose of 200 mg/kg, and significantly inhibited tumor growth with a tumor growth inhibition rate of 78.6% compared with the negative control group. Furthermore, phosphoantibody array analyses of a sample of the tumor suggested that <strong>16c</strong> inhibited the malignant proliferation of hepatocellular carcinoma (HCC) cells through decreasing the phosphorylation in the FAK cascade.</p>
chemistry, medicinal
What problem does this paper attempt to address?